Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of bomedemstat versus hydroxyurea in cytoreduction-naive essential thrombocythemia
CTR20250182Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in thrombocythemia comparing Bomedemstat with Hydroxyurea (2 arms). Primary endpoint: Durable clinical hematologic response. Started Dec 2025; status: active.
02
Drugs
bomedemstathydroxyurea
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on CTR20250182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250182.